# Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC

> **NCT02356653** · EARLY_PHASE1 · RECRUITING · sponsor: **Children's Hospital of Philadelphia** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia
- Inborn Errors of Metabolism
- Bone Marrow Failure Syndromes
- Immunodeficiencies
- Immunodysregulation Polyendocrinopathy Enteropathy X-linked Syndrome

## Interventions

- **BIOLOGICAL:** Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)

## Key facts

- **NCT ID:** NCT02356653
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-12
- **Primary completion:** 2027-01
- **Final completion:** 2030-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02356653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02356653, "Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02356653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*